Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: Implications for cancer gene therapy without tumor targeting

Journal of Gene Medicine

Volumn 2, Issue 1, 2000, Pages 11-21

  D'Orazi, Gabriella ^a,b   Marchetti, Alessandra ^a   Crescenzi, Marco ^a,c   Coen, Sabrina ^a   Sacchi, Ada ^a   Soddu, Silvia ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Proteolytic degradation; Recombinant adenovirus; Transacting activity; Tumor targeting

Indexed keywords

ADENOVIRIDAE;

BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; BETA GALACTOSIDASE; CHLORAMPHENICOL ACETYLTRANSFERASE; CYSTEINE PROTEINASE; DOXORUBICIN; LEUPEPTIN; MDM2 PROTEIN, MOUSE; MULTIENZYME COMPLEX; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEASOME; PROTEIN MDM2; PROTEIN P53; RECOMBINANT DNA; TUMOR PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; C3H MOUSE; CELL DIVISION; CELL LINE; CELL TRANSFORMATION; CHEMISTRY; CYTOLOGY; DNA DAMAGE; GENE EXPRESSION REGULATION; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM; MOUSE; MUSCLE; ONCOGENE RAS; PHYSIOLOGY; REPORTER GENE; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; BLOTTING, WESTERN; CELL DIVISION; CELL LINE; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CYSTEINE ENDOPEPTIDASES; DNA DAMAGE; DNA, RECOMBINANT; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENES, RAS; GENES, REPORTER; GENETIC VECTORS; LEUPEPTINS; MICE; MICE, INBRED C3H; MULTIENZYME COMPLEXES; MUSCLES; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033656021     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-2254(200001/02)2:1<11::aid-jgm81>3.0.co;2-k     Document Type: Article

References (41)

1. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994; 266: 1373-1376.
2. Etienne-Julan M, Roux P, Pourquard P, Carillo S, Jeanteur P, Piechaczyk M. Cell targeting by murine recombinant retroviruses. Bone Marrow Transplant 1992; 9: 139-142.
3. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A 1989; 86: 8763-8767.
4. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as suppressor of transformation. Cell 1989; 57: 1083-1093.
5. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wildtype p53. Science 1990; 249: 912-915.
6. Zhang W-W, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA. Safety evaluation of AdCMV-p53 in vitro and in vivo. Hum Gene Ther 1995; 6: 155-164.
7. Scardigli R, Bossi G, Blandino G, Crescenzi M, Soddu S, Sacchi A. Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging. Gene Ther 1997; 4: 1371-1378.
8. Blandino G, Scardigli R, Rizzo MG, Crescenzi M, Soddu S, Sacchi A. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene 1995; 10: 731-737.
9. Soddu S, Blandino G, Scardigli R, Martinelli R, Rizzo MG, Crescenzi M, Sacchi A. wt-p53 induces diverse effects in 32D cells expressing different oncogenes. Mol Cell Biol 1996; 16: 487-495.
10. Soddu S, Sacchi A. p53: Prospects for gene therapy. Cytokines, Cellular, and Molecular Therapy 1998; 4: 177-185.
11. Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977; 343: 76-79.
12. Crescenzi M, Crouch DH, Tatò F. Transformation by myc prevents fusion but not biochemical differentiation of C2C12 myoblasts: mechanisms of phenotypic correction in mixed culture with normal cells. J Cell Biol 1994; 125: 1137-1145.
13. Alemà S, and Tatò F. Oncogenes and muscle differentiation: multiple mechanisms of interference. Semin Cancer Biol 1994; 5: 147-156.
14. Del Bufalo D, Biroccio A, Soddu S, Laudonio N, D'Angelo C, Sacchi A, Zupi G. Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J Clin Invest 1996; 5: 1165-1173.
15. Dotto GP, Parada LF, Weinberg RA. Specific growth response of ras-transformed embryo fibroblasts to tumor promoter. Nature 1985; 318: 472-475.
16. Bacchetti S, Graham FL. Inhibition of cell proliferation by an adenovirus vector expressing the human wild type p53 protein. Int J Cancer 1993; 3: 781-788.
17. Jones N, Shenk T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 1979; 17: 683-689.
18. Graham F, Prevec L. Manipulation of adenovirus. In Methods of Molecular Biology, vol. 7, Murray EJ (ed). Clifton NJ: Humana Press, 1991; 109-128.
19. De Giovanni C, Nanni P, Sacchi A, Soddu S, Manni I, D'Orazi G, Bulfone-Paus S, Pohl T, Landuzzi L, Nicoletti G, Frabetti F, Rossi I, Lollini PL. Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells. Br J Cancer 1998; 78: 1541-1546.
20. Soddu S, Blandino G, Scardigli R, Coen S, Marchetti A, Rizzo MG, Bossi G, Cimino L, Crescenzi M, Sacchi A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol 1996; 134: 193-204.
21. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 252: 1708-1711.
22. Huff CA, Yuspa SH, Rosenthal D. Identification of control elements 3′ to the human keratin 1 gene that regulate cell type and differentiation-specific expression. J Biol Chem 1993; 268: 377-384.
23. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996; 1287: 77-102.
24. Biroccio A, Del Bufalo D, Ricca A, D'Angelo C, D'Orazi G, Sacchi A, Soddu S, Zupi G. Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration ashedule. Gene Ther 1999; 6: 1064-1072.
25. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997; 15: 1179-1189.
26. Maki CG, Huibregtse JM, Jones PM. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 1996; 56: 2649-2654.
27. Crook T, Marston NJ, Sara EA, Vousden KH. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 1994; 79: 817-827.
28. Pietenpol JA, Tokino T, Thiagalingam S, El-Deiry WS, Kinzler KW, Vogelstein BS. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A 1994; 91: 1998-2002.
29. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild-type p53 activity. EMBO J 1993; 12: 461-468.
30. Momand J, Zambetti GP, Olson D, George D, Levine A. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
31. Wu X, Bayle JH, Olson D, Levine A. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-1132.
32. Haupt Y, Maya R, Kazak A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
33. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
34. Siliciano JD, Canman CE, Taya Y, Sakaguchi E, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997; 11: 3471-3481.
35. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91: 325-334.
36. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee H-W, Cordon-Cardo C, DePihno R. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723.
37. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppressor pathways. Cell 1998; 92: 725-734.
38. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
39. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-208.
40. Gudas JM, Nguyen H, Klein RC, Katayose D. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res 1995; 1: 71-80.
41. Crescenzi M, Soddu S, Tatò F. Mitotic cycle reactivation in terminally differentiated cells by adenovirus infection. J Cell Physiol 1995; 162: 26-35.